IZTC Invizyne: יחס שווי שוק לערך בספרים
Integration risks into the supply chains of pharma behemoths are weighing on the credit profile of Invizyne Technologies Inc. (IZTC), yet the change in the market-to-book ratio demonstrates stable dynamics. The value -28.60 represents the current metric. Capitalization relies on the implementation of SimpleCell for compound synthesis, growing authority in biocatalysis, and the competition against traditional chemical synthesis.
%20-%20%D7%99%D7%97%D7%A1%20%D7%A9%D7%95%D7%95%D7%99%20%D7%A9%D7%95%D7%A7%20%D7%9C%D7%A0%D7%9B%D7%A1%D7%99%D7%9D%20%D7%A0%D7%A7%D7%99%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mvq8bmkb.8d-7aozthc&start=20220704&end=20261027&filename=GURU_Markets_-_IZTC_-_Invizyne-Technologies-Inc._-_Market-Cap-to-Net-Assets-Ratio "IZTC יחס שווי שוק לערך בספרים Invizyne Corp (14.11.2024 - 12.02.2025) | 👁️GURU.Markets👁️")
IZTC (Invizyne Technologies Inc): פילוחים אנליטיים ודוחות לפי אינדיקטורים
The SimpleCell cell-free platform provides Invizyne Technologies Inc. (IZTC) with unique pricing power in biopharmaceuticals. This metric reflects the degree of discounting of future profits by comparing market value to net assets. The ratio measures the premium the market is willing to pay for a technological advantage over book value. High values signal that the asset is overbought. By analyzing the ratio of the company's current market price to its book net assets, an investor assesses the risk of a price correction.